Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Peter Crooks to Vesicular Monoamine Transport Proteins

This is a "connection" page, showing publications Peter Crooks has written about Vesicular Monoamine Transport Proteins.

 
Connection Strength
  
 
 
7.491
  
  1. Hankosky ER, Joolakanti SR, Nickell JR, Janganati V, Dwoskin LP, Crooks PA. Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2017 12 15; 27(24):5467-5472.
    View in: PubMed
    Score: 0.583
  2. Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA. Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2016 09 15; 26(18):4441-4445.
    View in: PubMed
    Score: 0.536
  3. Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA. 1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2016 07 01; 26(13):2997-3000.
    View in: PubMed
    Score: 0.528
  4. Joolakanti SR, Nickell JR, Janganati V, Zheng G, Dwoskin LP, Crooks PA. Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2016 05 15; 26(10):2422-2427.
    View in: PubMed
    Score: 0.524
  5. Ding D, Nickell JR, Dwoskin LP, Crooks PA. Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2015 Jul 01; 25(13):2613-6.
    View in: PubMed
    Score: 0.492
  6. Ding D, Nickell JR, Deaciuc AG, Penthala NR, Dwoskin LP, Crooks PA. Synthesis and evaluation of novel azetidine analogs as potent inhibitors of vesicular [3H]dopamine uptake. Bioorg Med Chem. 2013 Nov 01; 21(21):6771-7.
    View in: PubMed
    Score: 0.436
  7. Penthala NR, Ponugoti PR, Nickell JR, Deaciuc AG, Dwoskin LP, Crooks PA. Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2). Bioorg Med Chem Lett. 2013 Jun 01; 23(11):3342-5.
    View in: PubMed
    Score: 0.425
  8. Crooks PA, Zheng G, Vartak AP, Culver JP, Zheng F, Horton DB, Dwoskin LP. Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem. 2011; 11(9):1103-27.
    View in: PubMed
    Score: 0.364
  9. Vartak AP, Gabriela Deaciuc A, Dwoskin LP, Crooks PA. Quinlobelane: a water-soluble lobelane analogue and inhibitor of VMAT2. Bioorg Med Chem Lett. 2010 Jun 15; 20(12):3584-7.
    View in: PubMed
    Score: 0.348
  10. Vartak AP, Nickell JR, Chagkutip J, Dwoskin LP, Crooks PA. Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2). J Med Chem. 2009 Dec 10; 52(23):7878-82.
    View in: PubMed
    Score: 0.338
  11. Zheng G, Dwoskin LP, Deaciuc AG, Crooks PA. Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2008 Dec 15; 18(24):6509-12.
    View in: PubMed
    Score: 0.312
  12. Zheng F, Zheng G, Deaciuc AG, Zhan CG, Dwoskin LP, Crooks PA. Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2. Bioorg Med Chem. 2007 Apr 15; 15(8):2975-92.
    View in: PubMed
    Score: 0.278
  13. Zheng G, Dwoskin LP, Crooks PA. Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J. 2006 Nov 10; 8(4):E682-92.
    View in: PubMed
    Score: 0.273
  14. Chandler CM, Nickell JR, George Wilson A, Culver JP, Crooks PA, Bardo MT, Dwoskin LP. Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats. Biochem Pharmacol. 2024 10; 228:116189.
    View in: PubMed
    Score: 0.228
  15. Lee NR, Zheng G, Leggas M, Janganati V, Nickell JR, Crooks PA, Bardo MT, Dwoskin LP. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine. J Pharmacol Exp Ther. 2019 11; 371(2):526-543.
    View in: PubMed
    Score: 0.165
  16. Lee NR, Zheng G, Crooks PA, Bardo MT, Dwoskin LP. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders. AAPS J. 2018 02 09; 20(2):29.
    View in: PubMed
    Score: 0.149
  17. Nickell JR, Siripurapu KB, Horton DB, Zheng G, Crooks PA, Dwoskin LP. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. Eur J Pharmacol. 2017 Jan 15; 795:143-149.
    View in: PubMed
    Score: 0.137
  18. Nickell JR, Siripurapu KB, Vartak A, Crooks PA, Dwoskin LP. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol. 2014; 69:71-106.
    View in: PubMed
    Score: 0.112
  19. Wilmouth CE, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. Pharmacol Biochem Behav. 2013 Nov; 112:29-33.
    View in: PubMed
    Score: 0.110
  20. Meyer AC, Neugebauer NM, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo. J Neurochem. 2013 Oct; 127(2):187-98.
    View in: PubMed
    Score: 0.109
  21. Horton DB, Nickell JR, Zheng G, Crooks PA, Dwoskin LP. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine. J Neurochem. 2013 Oct; 127(2):177-86.
    View in: PubMed
    Score: 0.109
  22. Alvers KM, Beckmann JS, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology (Berl). 2012 Nov; 224(2):255-62.
    View in: PubMed
    Score: 0.100
  23. Beckmann JS, Denehy ED, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology (Berl). 2012 Mar; 220(2):395-403.
    View in: PubMed
    Score: 0.096
  24. Horton DB, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J Pharmacol Exp Ther. 2011 Oct; 339(1):286-97.
    View in: PubMed
    Score: 0.095
  25. Horton DB, Siripurapu KB, Norrholm SD, Culver JP, Hojahmat M, Beckmann JS, Harrod SB, Deaciuc AG, Bardo MT, Crooks PA, Dwoskin LP. meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J Pharmacol Exp Ther. 2011 Mar; 336(3):940-51.
    View in: PubMed
    Score: 0.091
  26. Nickell JR, Zheng G, Deaciuc AG, Crooks PA, Dwoskin LP. Phenyl ring-substituted lobelane analogs: inhibition of [?H]dopamine uptake at the vesicular monoamine transporter-2. J Pharmacol Exp Ther. 2011 Mar; 336(3):724-33.
    View in: PubMed
    Score: 0.089
  27. Beckmann JS, Siripurapu KB, Nickell JR, Horton DB, Denehy ED, Vartak A, Crooks PA, Dwoskin LP, Bardo MT. The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. J Pharmacol Exp Ther. 2010 Dec; 335(3):841-51.
    View in: PubMed
    Score: 0.089
  28. Nickell JR, Krishnamurthy S, Norrholm S, Deaciuc G, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. J Pharmacol Exp Ther. 2010 Feb; 332(2):612-21.
    View in: PubMed
    Score: 0.084
  29. Zheng G, Dwoskin LP, Deaciuc AG, Crooks PA. Stereocontrolled synthesis and pharmacological evaluation of cis-2,6-diphenethyl-1-azabicyclo[2.2.2]octanes as lobelane analogues. J Org Chem. 2009 Aug 21; 74(16):6072-6.
    View in: PubMed
    Score: 0.083
  30. Zheng G, Horton DB, Deaciuc AG, Dwoskin LP, Crooks PA. Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 01; 16(19):5018-21.
    View in: PubMed
    Score: 0.067
  31. Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, Crooks PA. Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. J Med Chem. 2005 Aug 25; 48(17):5551-60.
    View in: PubMed
    Score: 0.063
  32. Zheng G, Dwoskin LP, Deaciuc AG, Zhu J, Jones MD, Crooks PA. Lobelane analogues as novel ligands for the vesicular monoamine transporter-2. Bioorg Med Chem. 2005 Jun 02; 13(12):3899-909.
    View in: PubMed
    Score: 0.062
  33. Miller DK, Crooks PA, Zheng G, Grinevich VP, Norrholm SD, Dwoskin LP. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J Pharmacol Exp Ther. 2004 Sep; 310(3):1035-45.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.